BG105470A - Means and method for the treament of tumours - Google Patents
Means and method for the treament of tumoursInfo
- Publication number
- BG105470A BG105470A BG105470A BG10547001A BG105470A BG 105470 A BG105470 A BG 105470A BG 105470 A BG105470 A BG 105470A BG 10547001 A BG10547001 A BG 10547001A BG 105470 A BG105470 A BG 105470A
- Authority
- BG
- Bulgaria
- Prior art keywords
- treament
- tumours
- acetyldinaline
- capecitabine
- gemcitabine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10180998P | 1998-09-25 | 1998-09-25 | |
| PCT/US1999/015386 WO2000018393A1 (en) | 1998-09-25 | 1999-07-08 | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105470A true BG105470A (en) | 2001-12-29 |
Family
ID=22286531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105470A BG105470A (en) | 1998-09-25 | 2001-04-25 | Means and method for the treament of tumours |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6469058B1 (ja) |
| EP (1) | EP1115391B1 (ja) |
| JP (1) | JP2002525320A (ja) |
| KR (1) | KR20010075348A (ja) |
| CN (1) | CN1319009A (ja) |
| AP (1) | AP2001002109A0 (ja) |
| AT (1) | ATE225655T1 (ja) |
| AU (1) | AU762079B2 (ja) |
| BG (1) | BG105470A (ja) |
| BR (1) | BR9913952A (ja) |
| CA (1) | CA2342981A1 (ja) |
| CZ (1) | CZ2001905A3 (ja) |
| DE (1) | DE69903458T2 (ja) |
| DK (1) | DK1115391T3 (ja) |
| EA (1) | EA200100369A1 (ja) |
| EE (1) | EE200100187A (ja) |
| ES (1) | ES2185378T3 (ja) |
| GE (1) | GEP20043199B (ja) |
| HK (1) | HK1040190A1 (ja) |
| HR (1) | HRP20010225B1 (ja) |
| HU (1) | HUP0103640A3 (ja) |
| ID (1) | ID30046A (ja) |
| IL (1) | IL141951A0 (ja) |
| IS (1) | IS5888A (ja) |
| NO (1) | NO20011493L (ja) |
| NZ (1) | NZ510504A (ja) |
| OA (1) | OA11659A (ja) |
| PL (1) | PL348673A1 (ja) |
| PT (1) | PT1115391E (ja) |
| SK (1) | SK3602001A3 (ja) |
| TR (1) | TR200100859T2 (ja) |
| WO (1) | WO2000018393A1 (ja) |
| YU (1) | YU22401A (ja) |
| ZA (1) | ZA200102233B (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1115391B1 (en) * | 1998-09-25 | 2002-10-09 | Warner-Lambert Company | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| BR0308250A (pt) * | 2002-03-04 | 2005-01-11 | Aton Pharma Inc | Métodos de indução de diferenciação terminal |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| JP2006508974A (ja) * | 2002-11-15 | 2006-03-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法 |
| US20060165744A1 (en) * | 2003-05-22 | 2006-07-27 | Neopharm, Inc | Combination liposomal formulations |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
| US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
| CN100443081C (zh) * | 2005-04-05 | 2008-12-17 | 吴一心 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
| US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
| US8229068B2 (en) | 2005-07-22 | 2012-07-24 | Tomotherapy Incorporated | System and method of detecting a breathing phase of a patient receiving radiation therapy |
| EP1907066A4 (en) | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | SYSTEM AND METHOD FOR THE ADMINISTRATION OF RADIATION THERAPY IN A POTENTIAL INTEREST |
| CA2616292A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treament plan |
| JP2009502251A (ja) | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | 放射線治療システムによって送達された線量を評価するシステム及び方法 |
| KR20080039926A (ko) * | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | 전달된 방사선량의 평가 방법 및 시스템 |
| US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
| JP5390855B2 (ja) | 2005-07-23 | 2014-01-15 | トモセラピー・インコーポレーテッド | ガントリおよび治療台の協調した動きを利用した放射線療法の撮像およびデリバリー |
| CN101534852B (zh) | 2006-08-31 | 2013-02-13 | 光谱医药公司 | 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化 |
| CA2713571C (en) * | 2008-01-28 | 2015-06-16 | Nanocarrier Co., Ltd. | Pharmaceutical composition or combination drug |
| FR2937867B1 (fr) * | 2008-11-03 | 2011-03-04 | Biorebus | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. |
| JP5687687B2 (ja) | 2009-04-06 | 2015-03-18 | 大塚製薬株式会社 | 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体 |
| WO2012003413A1 (en) * | 2010-06-30 | 2012-01-05 | The Broad Institute, Inc. | Novel solid forms of tacedinaline |
| US8729130B2 (en) | 2011-07-01 | 2014-05-20 | The Broad Institute, Inc. | Methods of using novel solid forms of tacedinaline |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| EP2711008A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer |
| EP2711009A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer |
| EP2711007A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer |
| CN105027227B (zh) | 2013-02-26 | 2017-09-08 | 安科锐公司 | 电磁致动的多叶准直器 |
| US10189797B2 (en) | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
| US11987579B2 (en) | 2018-07-30 | 2024-05-21 | Duke University | Niclosamide analogues and therapeutic use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5562925A (en) * | 1970-04-20 | 1996-10-08 | Research Corporation Tech. Inc. | Anti-tumor method |
| NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
| AU671491B2 (en) * | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| AU6878198A (en) | 1997-04-24 | 1998-11-13 | Warner-Lambert Company | Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| EP1115391B1 (en) * | 1998-09-25 | 2002-10-09 | Warner-Lambert Company | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
-
1999
- 1999-07-08 EP EP99935442A patent/EP1115391B1/en not_active Expired - Lifetime
- 1999-07-08 CZ CZ2001905A patent/CZ2001905A3/cs unknown
- 1999-07-08 SK SK360-2001A patent/SK3602001A3/sk unknown
- 1999-07-08 IL IL14195199A patent/IL141951A0/xx unknown
- 1999-07-08 WO PCT/US1999/015386 patent/WO2000018393A1/en not_active Application Discontinuation
- 1999-07-08 AT AT99935442T patent/ATE225655T1/de not_active IP Right Cessation
- 1999-07-08 YU YU22401A patent/YU22401A/sh unknown
- 1999-07-08 AP APAP/P/2001/002109A patent/AP2001002109A0/en unknown
- 1999-07-08 GE GEAP19995872A patent/GEP20043199B/en unknown
- 1999-07-08 KR KR1020017003794A patent/KR20010075348A/ko not_active Application Discontinuation
- 1999-07-08 NZ NZ510504A patent/NZ510504A/en unknown
- 1999-07-08 US US09/744,130 patent/US6469058B1/en not_active Expired - Fee Related
- 1999-07-08 HU HU0103640A patent/HUP0103640A3/hu unknown
- 1999-07-08 TR TR2001/00859T patent/TR200100859T2/xx unknown
- 1999-07-08 PT PT99935442T patent/PT1115391E/pt unknown
- 1999-07-08 EA EA200100369A patent/EA200100369A1/ru unknown
- 1999-07-08 JP JP2000571912A patent/JP2002525320A/ja active Pending
- 1999-07-08 ID IDW20010901A patent/ID30046A/id unknown
- 1999-07-08 EE EEP200100187A patent/EE200100187A/xx unknown
- 1999-07-08 OA OA1200100078A patent/OA11659A/en unknown
- 1999-07-08 PL PL99348673A patent/PL348673A1/xx not_active Application Discontinuation
- 1999-07-08 DK DK99935442T patent/DK1115391T3/da active
- 1999-07-08 DE DE69903458T patent/DE69903458T2/de not_active Expired - Fee Related
- 1999-07-08 CN CN99811320A patent/CN1319009A/zh active Pending
- 1999-07-08 ES ES99935442T patent/ES2185378T3/es not_active Expired - Lifetime
- 1999-07-08 CA CA002342981A patent/CA2342981A1/en not_active Abandoned
- 1999-07-08 BR BR9913952-9A patent/BR9913952A/pt not_active IP Right Cessation
- 1999-07-08 AU AU50921/99A patent/AU762079B2/en not_active Ceased
-
2001
- 2001-03-14 IS IS5888A patent/IS5888A/is unknown
- 2001-03-16 ZA ZA200102233A patent/ZA200102233B/en unknown
- 2001-03-23 NO NO20011493A patent/NO20011493L/no not_active Application Discontinuation
- 2001-03-23 HR HR20010225A patent/HRP20010225B1/xx not_active Application Discontinuation
- 2001-04-25 BG BG105470A patent/BG105470A/xx unknown
-
2002
- 2002-03-01 HK HK02101589.3A patent/HK1040190A1/zh unknown
- 2002-10-08 US US10/184,309 patent/US20030170300A1/en not_active Abandoned
- 2002-10-09 US US10/185,221 patent/US20030086965A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105470A (en) | Means and method for the treament of tumours | |
| IL100942A0 (en) | 2,4-diaminoquinazoline derivatives for enhancing antitumor activity | |
| MXPA01004648A (es) | Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20. | |
| AU2592600A (en) | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
| HU9301314D0 (en) | Quinazoline derivatves for improving anto-tumouric activity | |
| GB9818916D0 (en) | Use | |
| SG144712A1 (en) | Nordihydroguaiartic derivaties for use in treatment of tumors | |
| NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
| IL134445A0 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
| MY137303A (en) | Methods for treating proliferative diseases | |
| NZ512210A (en) | Camptothecin analogs useful for treating cancer and leukemia | |
| EP0225759A3 (en) | Interferon compositions | |
| HU9701060D0 (en) | Pharmaceutical composition for treating cognitive disturbs | |
| IL131478A0 (en) | Methods for treatment of scar tissue | |
| EP0938900A4 (en) | MEANS OF PREVENTION OR HEALING OF STOMATITIS | |
| HUP0200717A3 (en) | Radioactive cisplatin in the treatment of cancer | |
| ZA200101188B (en) | DNAzymes and methods for treating restenosis. | |
| EP1083914A4 (en) | TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS | |
| IL133141A0 (en) | Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps | |
| ATE179987T1 (de) | Vitamin b 12-haltige sanddornkonzentrate oder - extrakte | |
| CA2259997A1 (en) | Remedies and preventives for stomatitis | |
| RU96107442A (ru) | Способ лечения вегетативной дистонии с парасимпатическими пароксизмами | |
| SI1115391T1 (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
| SI1066041T1 (sl) | Uporaba 17-alfa-estradiolnih derivatov za terapijo stranskih ucinkov med in/ali po GnRHa terapiji |